EXTENDING THE SURVIVAL OF HR+ BREAST CANCER PATIENTS RECEIVING CDK4/6 INHIBITORS BY TARGETING IL 17-PRODUCING GAMMA DELTA T CELLS

Weill Medical College Of Cornell University

Investigators